Taclonex Scalp (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is called Xamiol outside the US.
Warner Chilcott is Leo Pharma’s exclusive licensee of Taclonex and Dovonex products in the US. Warner Chilcott expects to launch Taclonex Scalp in the second half of 2008. As a result of the FDA approval of Taclonex Scalp, Warner Chilcott will pay a milestone payment of $40 million to Leo Pharma in June 2008.
Roger Boissonneault, CEO of Warner Chilcott, said: “Taclonex Scalp represents an exciting addition to our Taclonex and Dovonex franchise, expanding the treatment options for psoriasis patients in the US.”